ATE433115T1 - Timp-2 als ziel/marker des versagens von beta- zellen - Google Patents
Timp-2 als ziel/marker des versagens von beta- zellenInfo
- Publication number
- ATE433115T1 ATE433115T1 AT05760716T AT05760716T ATE433115T1 AT E433115 T1 ATE433115 T1 AT E433115T1 AT 05760716 T AT05760716 T AT 05760716T AT 05760716 T AT05760716 T AT 05760716T AT E433115 T1 ATE433115 T1 AT E433115T1
- Authority
- AT
- Austria
- Prior art keywords
- timp
- marker
- target
- cell failure
- beta cell
- Prior art date
Links
- 102000005354 Tissue Inhibitor of Metalloproteinase-2 Human genes 0.000 title abstract 2
- 108010031372 Tissue Inhibitor of Metalloproteinase-2 Proteins 0.000 title abstract 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 title abstract 2
- 239000003550 marker Substances 0.000 title 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 2
- 206010061818 Disease progression Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 230000005750 disease progression Effects 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/81—Protease inhibitors
- G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- G01N2333/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04103608 | 2004-07-28 | ||
| PCT/EP2005/007853 WO2006010529A1 (en) | 2004-07-28 | 2005-07-19 | Timp-2 as target/marker of beta cell failure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE433115T1 true ATE433115T1 (de) | 2009-06-15 |
Family
ID=34972635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05760716T ATE433115T1 (de) | 2004-07-28 | 2005-07-19 | Timp-2 als ziel/marker des versagens von beta- zellen |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20100009462A1 (de) |
| EP (1) | EP1774338B1 (de) |
| JP (1) | JP4562771B2 (de) |
| CN (1) | CN1993619A (de) |
| AT (1) | ATE433115T1 (de) |
| CA (1) | CA2574417C (de) |
| DE (1) | DE602005014778D1 (de) |
| ES (1) | ES2325789T3 (de) |
| WO (1) | WO2006010529A1 (de) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3112871B1 (de) | 2009-12-20 | 2020-07-29 | Astute Medical, Inc. | Verfahren und zusammensetzungen zur diagnose und prognose von nierenläsion und niereninsuffizienz |
| EP3540440B1 (de) | 2011-12-08 | 2022-09-28 | Astute Medical, Inc. | Verfahren und verwendungen zur bewertung von nierenschäden und nierenstatus |
| EP3361255B1 (de) | 2013-01-17 | 2020-03-11 | Astute Medical, Inc. | Verfahren und zusammensetzungen zur diagnose und prognose von nierenläsion und niereninsuffizienz |
| BR112016002685A2 (pt) | 2013-08-07 | 2018-01-30 | Astute Medical Inc | ensaios para timp2 que apresentam melhor desempenho em amostras biológicas |
| JP2016540759A (ja) | 2013-12-03 | 2016-12-28 | アスチュート メディカル，インコーポレイテッド | 腎損傷および腎不全の診断および予後のための方法および組成物 |
| EP3281011B1 (de) | 2015-04-09 | 2024-06-05 | Astute Medical, Inc. | Verfahren und zusammensetzungen zur diagnose und prognose von nierenläsion und niereninsuffizienz |
| CA3026502A1 (en) | 2016-06-06 | 2017-12-14 | Astute Medical, Inc. | Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2 |
| US10224053B2 (en) * | 2017-03-24 | 2019-03-05 | Hyundai Motor Company | Audio signal quality enhancement based on quantitative SNR analysis and adaptive Wiener filtering |
| US11718682B2 (en) | 2017-04-05 | 2023-08-08 | Astute Medical, Inc. | Assays for TIMP2 having improved performance in biological samples |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2265345T3 (es) * | 1999-05-24 | 2007-02-16 | SHIONOGI & CO., LTD. | Metodo de evaluacion de la actividad inhibidora de metaloproteinasa de la matriz in vivo. |
| US6673623B1 (en) * | 2000-09-12 | 2004-01-06 | Novocure, Inc. | Methods and compositions that control lipid production |
| AUPS282002A0 (en) * | 2002-06-06 | 2002-06-27 | Gropep Limited | Metalloproteinase inhibitors |
-
2005
- 2005-07-19 ES ES05760716T patent/ES2325789T3/es not_active Expired - Lifetime
- 2005-07-19 JP JP2007522979A patent/JP4562771B2/ja not_active Expired - Fee Related
- 2005-07-19 US US11/658,517 patent/US20100009462A1/en not_active Abandoned
- 2005-07-19 WO PCT/EP2005/007853 patent/WO2006010529A1/en not_active Ceased
- 2005-07-19 EP EP05760716A patent/EP1774338B1/de not_active Expired - Lifetime
- 2005-07-19 CN CNA2005800256144A patent/CN1993619A/zh active Pending
- 2005-07-19 DE DE602005014778T patent/DE602005014778D1/de not_active Expired - Lifetime
- 2005-07-19 AT AT05760716T patent/ATE433115T1/de not_active IP Right Cessation
- 2005-07-19 CA CA2574417A patent/CA2574417C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2574417C (en) | 2010-09-28 |
| EP1774338A1 (de) | 2007-04-18 |
| CN1993619A (zh) | 2007-07-04 |
| JP4562771B2 (ja) | 2010-10-13 |
| WO2006010529A1 (en) | 2006-02-02 |
| US20100009462A1 (en) | 2010-01-14 |
| JP2008508502A (ja) | 2008-03-21 |
| DE602005014778D1 (de) | 2009-07-16 |
| ES2325789T3 (es) | 2009-09-17 |
| CA2574417A1 (en) | 2006-02-02 |
| EP1774338B1 (de) | 2009-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE528300T1 (de) | Bizyklische verbindungen und ihre verwendung als antidiabetika | |
| WO2008030273A3 (en) | Compositions and methods for diagnosis and treatment of type 2 diabetes | |
| WO2006084195A3 (en) | Personal assessment including familial risk analysis for personalized disease prevention plan | |
| EA200971079A1 (ru) | ГЕНЕТИЧЕСКИЕ ВАРИАНТЫ В Chr5p12 И 10q26 В КАЧЕСТВЕ МАРКЕРОВ ДЛЯ ПРИМЕНЕНИЯ ПРИ ОЦЕНКЕ РИСКА, ДИАГНОСТИРОВАНИИ, ПРОГНОЗИРОВАНИИ И ЛЕЧЕНИИ РАКА ГРУДИ | |
| WO2009059150A3 (en) | Biomarkers for fatty liver disease and methods using the same | |
| EP1547996A4 (de) | Diagnostische sonden und heilmittel für krankheiten, bei denen prionprotein akkumuliert wird, und anfürbereagenzien für prionprotein | |
| ATE456055T1 (de) | Diagnoseverfahren für erkrankungen im zusammenhang mit hirnschäden | |
| ES2572372T3 (es) | Método de diagnóstico de enfermedades neurodegenerativas basado en la medición de los niveles o de la actividad de SIRT1 | |
| ATE476657T1 (de) | Vorhersage von letalität und detektion von schweren erkrankungen | |
| EA201190043A1 (ru) | Имидазопиразиновые ингибиторы syk | |
| ATE535612T1 (de) | Toxizitätsscreeningverfahren | |
| EA200800087A1 (ru) | Генетические варианты гена tcf7l2 как диагностические маркеры риска возникновения сахарного диабета ii типа | |
| WO2008122670A3 (en) | Human diabetes susceptibility tnfrsf10b gene | |
| DK2005162T3 (da) | Screeningsmetode | |
| WO2006084101A3 (en) | Method and apparatus for determining familial risk of disease | |
| WO2007134028A3 (en) | Biomarkers for depression and methods using the same | |
| WO2009019370A3 (fr) | Procede de dosage de l'apolipoproteine aii pour le diagnostic in vitro du cancer colorectal | |
| ATE433115T1 (de) | Timp-2 als ziel/marker des versagens von beta- zellen | |
| WO2011143575A3 (en) | smFRET WITH MEMBRANE PROTEINS | |
| WO2006133287A3 (en) | Expression profiles of peripheral blood mononuclear cells for inflammatory bowel diseases | |
| ATE468535T1 (de) | Verwendung von nnmt als marker für lungenkrebs | |
| DE602008004556D1 (de) | Zusammensetzungen und verfahren zum nachweis von störungen in verbindung mit histamin | |
| WO2006010533A3 (en) | Pancreatic polypeptide as target/marker of beta cell failure | |
| DE602005010712D1 (de) | Insulinpromotor-faktor 1 als target/marker von beta-zellen-störung | |
| WO2010121834A3 (en) | Irak kinase family as novel target and biomarker for alzheimer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |